For security, Pfizer watches suppliers

"Do not enter into supply agreements with companies that do not meet acceptable standards, and terminate agreements with companies that do not maintain acceptable standards." So says Gerry Migliaccio, senior VP for global manufacturing at Pfizer, in a Pharmaceutical Technology interview.

He says that's an oversimplification of one of the key elements of enforcement in a strategy for supply-chain security. Many factors are involved in evaluating suppliers, notes Migliaccio. But once basic viability has been established, he looks at their quality systems and environmental-management systems.

Migliaccio also notes in the interview that control of the suppliers to Pfizer's suppliers is among then most critical of supply chain security issues.

- see the article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.